By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Affimed Therapeutics AG 

Im Neuenheimer Feld 582
Heidelberg    69120   Germany
Phone: 49-6221-65307-0 Fax: 49-6221-65307-77



Company News
Immuno-Oncology Biotech Affimed Therapeutics AG Files For $75 Million IPO 6/30/2014 7:06:04 AM
Affimed Therapeutics AG Highlights Further Data On AFM13, A Bispecific CD30/CD16A TandAb in Development To Treat Hodgkin Lymphoma, At The 2014 American Association for Cancer Research Annual Meeting 4/10/2014 7:49:05 AM
The Leukemia & Lymphoma Society and Affimed Therapeutics AG Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients 9/16/2013 11:00:04 AM
Affimed Therapeutics AG Reports Phase 1 Clinical Data for Its Immunotherapy AFM13 in Relapsing/Refractory Hodgkin Lymphoma Patients 6/24/2013 11:28:16 AM
Affimed Therapeutics AG Raises $20 Million in a Series D Financing Round 10/8/2012 7:38:13 AM
Affimed Therapeutics AG Raises E 20 million in a Series C Financing Round 4/29/2010 7:24:52 AM
Affimed Therapeutics AG Successfully Completes Preclinical Development of AFM 13 2/8/2010 9:18:28 AM
Affimed Therapeutics AG Completes Move Into Drug Development 1/14/2010 11:16:28 AM
Affimed Therapeutics AG Receives FDA Orphan Drug Designation for AFM13 against Hodgkin Lymphoma 9/15/2009 1:38:24 PM
Affimed Therapeutics AG Joins the Molecular Imaging Technology Initiative 2/9/2009 1:05:25 PM